Compare SCNX & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCNX | NEUP |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 21.7M |
| IPO Year | 2020 | N/A |
| Metric | SCNX | NEUP |
|---|---|---|
| Price | $0.39 | $3.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 604.9K | 31.1K |
| Earning Date | 03-25-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $653,391.00 | ★ $15,649,448.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 207.88 | N/A |
| 52 Week Low | $0.42 | $3.65 |
| 52 Week High | $3.61 | $21.40 |
| Indicator | SCNX | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 32.23 | 48.50 |
| Support Level | $0.42 | $3.94 |
| Resistance Level | $0.48 | $4.09 |
| Average True Range (ATR) | 0.03 | 0.10 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 6.78 | 45.83 |
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.